Rigel Announces Third Quarter 2009 Financi...(38135 36581 37185 35837 ...),Health

Date:11/3/2009

38,135 36,581 37,185 35,837 ====== ====== ====== ====== ---------- Note A Stock-based compensation expense included in: Research and development $2,356 $3,035 $6,309 $9,229 General and administrative 1,176 3,001 3,226 8,572 Restructuring charges - - 122 - --- --- --- --- $3,532 $6,036 $9,657 $17,801 ====== ====== ====== ======= SUMMARY BALANCE SHEET DATA (in thousands) September 30, December 31, 2009 2008(1) ---- ------ (unaudited) Cash, cash equivalents and available for sale securities $156,078 $134,477 Total assets 164,295 143,858 Stockholders' equity 130,308 104,165 (1) Derived from audited financial statements

SOURCE Rigel Pharmaceuticals, Inc.

'/>"/>

SOURCE Rigel Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Rigel Announces Presentations at Two Investor Conferences
2. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
3. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
4. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
9. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
10. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders